Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.46 USD
Change Today +0.0175 / 3.99%
Volume 3.9M
SNTA On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (SNTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $3.27
52 Week Low
11/16/15 - $0.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

synta pharmaceuticals corp (SNTA) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (SNTA) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; Elesclomol, a mitochondria-targeting agent that is in Phase II clinical trial for ovarian cancer; and CRACM ion channel inhibitors and IL-12/23 inhibitors for the treatment of inflammatory diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

33 Employees
Last Reported Date: 11/5/15
Founded in 2000

synta pharmaceuticals corp (SNTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $77.5K
Executive Chairman, Chairman of Nominating & ...
Total Annual Compensation: --
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $21.0K
Compensation as of Fiscal Year 2014.

synta pharmaceuticals corp (SNTA) Key Developments

Synta Pharmaceuticals Corp. Announces Reduction of Workforce; Announces Management Changes

Synta Pharmaceuticals Corp. announced that it is reducing its workforce by approximately 60% to 33 full time employees. The company announced, as part of the restructuring, on November 3, 2015, Vojo Vukovic, M.D., Ph.D., the company's Senior Vice President, Chief Medical Officer, was notified that his employment would be terminated effective immediately. On October 30, 2015, the board appointed Scott Morenstein as a director effective November 3, 2015. Mr. Morenstein will serve as a Class II director until the 2018 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified. Mr. Morenstein has also been appointed to serve on Audit Committee of the Board of Directors.

Synta Pharmaceuticals Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Synta Pharmaceuticals Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported a net loss of $17.628 million or $0.13 per basic and diluted share compared to $19.966 million or $0.19 per basic and diluted share a year ago. Loss from operations was $17.394 million against $19.449 million for the same period a year ago. For the nine months, the company reported a net loss of $58.135 million or $0.46 per basic and diluted share compared to $65.809 million or $0.69 per basic and diluted share for the same period a year ago. Loss from operations was $57.23 million against $64.057 million for the same period a year ago.

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer

Synta Pharmaceuticals Corp. announced that the company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small cell lung adenocarcinoma. Based on the review of a pre-planned interim analysis, the study's Independent Data Monitoring Committee (IDMC) concluded that the addition of ganetespib to docetaxel is unlikely to demonstrate a statistically significant improvement in the primary endpoint of overall survival compared to docetaxel alone. The IDMC noted that the combination of ganetespib and docetaxel was generally well tolerated in the study, with an adverse event profile consistent with previous studies combining these agents. GALAXY-2 is a Phase 3 global, randomized, multi-center trial. Synta continues to support enrollment in four additional large, randomized, multi-center investigator-sponsored studies, including: the GANNET53 trial of ganetespib and paclitaxel in ovarian cancer; the AML LI-1 trial of ganetespib with low dose cytarabine (Ara-C) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS); the AML18 trial of ganetespib with standard DA (daunorubicin and Ara-C) in AML and high-risk MDS; and the I-SPY 2 TRIAL of ganetespib and standard chemotherapy in women with newly diagnosed, locally advanced breast cancer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTA:US $0.46 USD +0.0175

SNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTA.
View Industry Companies

Industry Analysis


Industry Average

Valuation SNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SYNTA PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at